News

Artificial Intelligence

Asia

China-led Team Builds AI Model to Predict Human Organ Aging

A new AI model from Xi'an Jiaotong University uses protein data to predict the biological age of 13 specific organs and identify disease risks.

A new AI model from Xi'an Jiaotong University uses protein data to predict the biological age of 13 specific organs and identify disease risks.

A new AI model from Xi'an Jiaotong University uses protein data to predict the biological age of 13 specific organs and identify disease risks.

NewDecoded

Published Jan 8, 2026

Jan 8, 2026

5 min read

A pioneering research team at Xi'an Jiaotong University has mapped the genetic landscape of aging across 13 different human organs. By integrating large scale data from the UK Biobank, the study challenges the traditional view of aging as a uniform systemic process. Their findings, published in Nature Communications, suggest that individuals possess a mosaic of biological ages within a single body. This research marks a fundamental shift from monitoring overall health to identifying specific internal systems that are declining prematurely.

The researchers built their predictive models using an Elastic Net machine learning algorithm trained on plasma protein signatures from over 50,000 participants. This AI identifies specific molecular clocks by tracking proteins that originate from specific tissues like the heart, brain, and kidneys. This breakthrough allows for high precision tracking of organ health without the need for invasive biopsies. It transforms the way scientists observe the hidden biological decay that often precedes chronic illness.

One of the most striking discoveries identifies the ABO blood group gene as a master regulator of multi-organ aging. The study found that individuals with Type O blood show accelerated aging in their arteries and gut, while Type A individuals exhibit faster pancreatic aging. This suggests that basic blood type data could soon dictate personalized health monitoring strategies and early screening protocols. It provides a biological explanation for why certain people face specific health risks despite leading healthy lives.

Using Mendelian Randomization, the team moved beyond simple correlations to establish firm causal links between organ decline and chronic disease. They demonstrated that kidney aging serves as a primary driver for hypertension, while heart and muscle aging directly increase the risk of heart failure. These results indicate that specific organ clocks can serve as early warning systems for life threatening conditions. This insight allows doctors to target the root cause of systemic diseases before they manifest clinically.

External lifestyle choices were also shown to have highly localized impacts on biological aging. Smoking drastically accelerates the clocks of the lungs, gut, kidneys, and stomach, while regular alcohol consumption specifically targets brain aging. This level of detail provides a roadmap for individuals to make targeted lifestyle modifications based on their own unique biological vulnerabilities. It underscores the fact that personal habits do not affect the whole body equally but target specific weak points.

While currently a research tool, the translation of this technology into clinical practice is expected to accelerate in the coming years. Experts believe proteomic aging tests could become available in specialized diagnostic labs within three to five years. This shift would allow healthcare providers to move from treating established diseases to managing the biological aging process as it happens. As testing costs decrease, these molecular clocks could become a standard part of annual health checkups.


Decoded Take

Decoded Take

Decoded Take

The transition from systemic aging to organ-specific diagnostics marks a turning point for the longevity industry. By moving away from generic wellness advice, healthcare providers can now pivot toward targeted interventions based on an individual's unique genetic vulnerabilities. This data-driven approach not only improves drug repurposing for age-related diseases but also sets the stage for a new era of personalized medicine where biological age, rather than chronological age, dictates clinical priorities.

Share this article

Related Articles

Related Articles

Related Articles